良性前列腺增生治疗的研究进展
摘要
移行区约占前列腺的5%，是围绕近端尿道的部分。该区域组织持续生长常常伴随男性一生。老年男性BPH的发生与
下尿路梗阻症状（LUTS）密切相关，下尿路症状由多种症状定义，包括尿急、夜尿、尿频、排尿困难、排尿困难、
排尿困难以及排尿时尿流微弱或中断。尽管一些LUTS被定义为“独立于BPH的LUTS”，但BPH及其下游影响导致
许多男性出现慢性LUTS。本文对现有治疗良性前列腺增生的不同治疗方式进行综述。
关键词
全文:
PDF参考
[1]Oelke M, Bachmann A, Descazeaud A, et al. EAU
Guidelines on the Treatment and Follow-up of Nonneurogenic Male Lower Urinary Tract Symptoms Including
Benign Prostatic Obstruction[J]. European Urology, 2013,
64(1): 118-140.
[2]Cho A, Chughtai B, Te A E. Benign Prostatic
Hyperplasia and Male Lower Urinary Tract Symptoms:
Epidemiology and Risk Factors[J]. Current Bladder
Dysfunction Reports, 2020, 15(2): 60-65.
[3]Aaron L, Franco O E, Hayward S W. Review of
Prostate Anatomy and Embryology and the Etiology of
Benign Prostatic Hyperplasia[J]. Urologic Clinics of North
America, 2016, 43(3): 279-288.
[4]An J, Kong H. c c[J]. PLOS ONE, 2022, 17(5):
e0268695.
[5]Liu C C, Huang S P, Li W M, et al. Relationship
Between Serum Testosterone and Measures of Benign
Prostatic Hyperplasia in Aging Men[J]. Urology, 2007, 70(4):
677-680.
[6]The management of lower urinary tract symptoms in
men - Bohrium[EB].
[7]Lerner L B, McVary K T, Barry M J, et al.
Management of Lower Urinary Tract Symptoms Attributed
to Benign Prostatic Hyperplasia: AUA Guideline Part II—
Surgical Evaluation and Treatment[J]. Journal of Urology,
2021, 206(4): 818-826.
[8]Franco J V, Garegnani L, Liquitay C M E, et al.
Transurethral microwave thermotherapy for the treatment of
lower urinary tract symptoms in men with benign prostatic
hyperplasia[J]. Cochrane Database of Systematic Reviews,
2021(6).
[9]Chee K C H, Ibrahim M F, Md Z Z. A prospective,
randomized clinical trial comparing bipolar plasma kinetic
resection of the prostate versus conventional monopolar
transurethral resection of the prostate in the treatment of
benign prostatic hyperplasia[J]. Annals of Saudi Medicine,
2009, 29(6): 429-432.
[10]Efficacy and safety of prostatic artery embolization
for benign prostatic hyperplasia: A systematic review and
meta-analysis of randomized controlled trials - Bohrium[EB].
[11]Herschorn S, Jones J S, Oelke M, et al. Efficacy and
Tolerability of Fesoterodine in Men With Overactive Bladder:
A Pooled Analysis of 2 Phase III Studies[J]. Urology, 2010,
75(5): 1149-1155.
[12]Schaefer W. Re: Safety and Tolerability of
Tolterodine for the Treatment of Overactive Bladder in Men
With Bladder Outlet Obstruction: P. Abrams, S. Kaplan, H.
J. De Koning Gans and R. Millard J Urol, 175: 999–1004,
2006[J]. Journal of Urology, 2006, 176(5): 2311-2313.
[13]Khullar V, Amarenco G, Angulo J C, et al. Efficacy
and Tolerability of Mirabegron, a β3-Adrenoceptor
Agonist, in Patients with Overactive Bladder: Results from a
Randomised European–Australian Phase 3 Trial[J]. European
Urology, 2013, 63(2): 283-295.
[14]Chapple C R, Kaplan S A, Mitcheson D, et al.
Randomized Double-blind, Active-controlled Phase 3
Study to Assess 12-Month Safety and Efficacy of Mirabegron,
a β3-Adrenoceptor Agonist, in Overactive Bladder[J].
European Urology, 2013, 63(2): 296-305.
[15]Yamaguchi O, Kakizaki H, Homma Y, et al.
Solifenacin as Add-on Therapy for Overactive Bladder
Symptoms in Men Treated for Lower Urinary Tract
Symptoms— ASSIST, Randomized Controlled Study[J].
Urology, 2011, 78(1): 126-133.
[16]Kaplan S A, Lee J Y, Meehan A G, et al. TimeCourse of Incident Adverse Experiences Associated with
Doxazosin, Finasteride and Combination Therapy in Men
with Benign Prostatic Hyperplasia: The MTOPS Trial[J]. The
Journal of Urology, 2016, 195(6): 1825-1829.
[17]Kim H J, Sun H Y, Choi H, et al. Efficacy and
Safety of Initial Combination Treatment of an Alpha Blocker
with an Anticholinergic Medication in Benign Prostatic
Hyperplasia Patients with Lower Urinary Tract Symptoms:
Updated Meta-Analysis[J]. PLoS One, 2017.
[18]Wagg A, Staskin D, Engel E, et al. Efficacy, safety,
and tolerability of mirabegron in patients aged ≥ 65 yr
with overactive bladder wet: a phase IV, double-blind,
randomised, placebo-controlled study (PILLAR)[J]. European
Urology, 2020, 77(2): 211-220.
[19]Liu Y, Lu J, Xiao C, et al. Impact on Sexual Function
of Endoscopic Enucleation Versus Transurethral Resection
of the Prostate for Lower Urinary Tract Symptoms Due to
Benign Prostatic Hyperplasia: A Systematic Review and MetaAnalysis[J]. Journal of endourology, 2020, 203(10): E492.
[20]Sakalis V I, Karavitakis M, Bedretdinova D,et al.
Medical Treatment of Nocturia in Men with Lower Urinary
Tract Symptoms: Systematic Review by the European
Association of Urology Guidelines Panel for Male Lower
Urinary Tract Symptoms[J]. European Urology, 2017, 72(5):
757-769.
[21]Roehrborn C G, Siami P, Barkin J, et al. The Effects
of Combination Therapy with Dutasteride and Tamsulosin
on Clinical Outcomes in Men with Symptomatic Benign
Prostatic Hyperplasia: 4-Year Results from the CombAT
Study[J]. European Urology, 2010, 57(1): 123-131.
[22]Allison S J, Gibson W. Mirabegron, alone and in
combination, in the treatment of overactive bladder: realworld evidence and experience[J]. Therapeutic Advances in
Urology, 2018, 10(12): 411-419.
[23]Van Kerrebroeck P, Chapple C, Drogendijk T, et al.
Combination Therapy with Solifenacin and Tamsulosin Oral
Controlled Absorption System in a Single Tablet for Lower
Urinary Tract Symptoms in Men: Efficacy and Safety Results
from the Randomised Controlled NEPTUNE Trial[J].
European Urology, 2013, 64(6): 1003-1012.
[24]Tolterodine and tamsulosin for treatment of men
with lower urinary tract symptoms and overactive bladder: a
randomized controlled tria - Bohrium[EB].
[25]Miernik A, Gratzke C. Current Treatment for
Benign Prostatic Hyperplasia[J]. Deutsches Ärzteblatt
International, 2020, 117(49): 843.
[26]Rassweiler J, Teber D, Kuntz R,et al. Complications
of Transurethral Resection of the Prostate (TURP)—
Incidence, Management, and Prevention[J]. European
Urology, 2006, 50(5): 969-980.
[27]Cetti R J, Hicks J A, Venn S N, et al. RESULTS
FROM AN INTERNATIONAL MULTICENTRE
DOUBLE‐BLIND RANDOMIZED CONTROLLED
TRIAL ON THE PERIOPERATIVE EFFICACY
AND SAFETY OF BIPOLAR VS MONOPOLAR
T R A N S U R E T H R A L R E S E C T I O N O F T H E
PROSTATE[J]. BJU International, 2012, 109(11).
[28]Mamoulakis C, Trompetter M, De La Rosette J.
Bipolar transurethral resection of the prostate: the ‘golden
standard’ reclaims its leading position:[J]. Current Opinion in
Urology, 2009, 19(1): 26-32.
[29]Lerner L, Parsons J, Dahm P, et al. Surgical
Management of Lower Urinary Tract Symptoms Attributed
to Benign Prostatic Hyperplasia: AUA Guideline Amendment
2020.[J]. Journal of Urology, 2020.
[30]夏中友，伍季，李云祥，等.内镜下不同术式
的前列腺剜除术疗效对比[J].西部医学，2022，34（2）：
225-228+234.
[31]Xue B, Zang Y, Zhang Y, et al. GreenLight HPS
120-W laser vaporization versus transurethral resection of
the prostate for treatment of benign prostatic hyperplasia: A
prospective randomized trial[J]. Journal of X-Ray Science
and Technology, 2013, 21(1): 125-132.
[32]Kuntzman R S, Malek R S, Barrett D M. HighPower Potassium Titanyl Phosphate Laser Vaporization
Prostatectomy[J]. Mayo Clinic Proceedings, 1998, 73(8):
798-801.
[33]Lan Y. Thulium (Tm:YAG) laser vaporesection
of prostate and bipolar transurethral resection of prostate in
patients with benign prostate hyperplasia: a systematic review
and meta-analysis[J]. Lasers Med Sci, 2018.
[34]Porpiglia F, Fiori C, Bertolo R, et al. 3-yearfollow-up of temporary implantable nitinol device
implantation for the treatment of benign prostatic obstruction.
[J]. BJU International, 2018, 122(1): 106-112.
[35]Chen D C, Qu L, Webb H, et al. Aquablation in
men with benign prostate hyperplasia: A systematic review
and meta-analysis[J]. Current Urology, 2023, 17(1).
[36]Kaplan S A. Re: rezūm Water Vapor Thermal
Therapy for Lower Urinary Tract Symptoms Associated
with Benign Prostatic Hyperplasia: 4-Year Results from
Randomized Controlled Study[J]. Journal of Urology, 2019,
202(1): 5-5.
[37]De Assis A M, Moreira A M, Carnevale F C,et al.
Role of Ultrasound Elastography in Patient Selection for
Prostatic Artery Embolization[J]. Journal of Vascular and
Interventional Radiology, 2021, 32(10): 1410-1416.
[38]Cerri G, Carnevale F, Antunes A, et al. MRI
findings after prostatic artery embolization for treatment
of benign hyperplasia.[J]. AJR. American journal of
roentgenology, 2014.
[39]Napal Lecumberri S, Insausti Gorbea I, Sáez De
Ocariz García A, et al. Prostatic artery embolization versus
transurethral resection of the prostate in the treatment of
benign prostatic hyperplasia: protocol for a non-inferiority
clinical trial[J]. Research and Reports in Urology, 2018,
Volume 10: 17-22.
[40]Bhatia S, Sinha V K, Harward S, et al. Prostate
Artery Embolization in Patients with Prostate Volumes of 80
mL or More: A Single-Institution Retrospective Experience
of 93 Patients[J]. Journal of Vascular and Interventional
Radiology, 2018, 29(10): 1392-1398.
[41]Bhatia S, Sinha V K, Kava B R, et al. Efficacy of
Prostatic Artery Embolization for Catheter-Dependent
Patients with Large Prostate Sizes and High Comorbidity
Scores[J]. Journal of Vascular and Interventional Radiology,
2018, 29(1): 78-84.e1.
[42]Wu X, Zhou A, Heller M, et al. Prostatic Artery
Embolization Versus Transurethral Resection of the Prostate
for Benign Prostatic Hyperplasia: A Cost-Effectiveness
Analysis[J]. Journal of Vascular and Interventional Radiology,
2022, 33(12): 1605-1615.
[43]Hashem E, Elsobky S, Khalifa M. Prostate Artery
Embolization for Benign Prostate Hyperplasia Review:
Patient Selection, Outcomes, and Technique[J]. Seminars in
Ultrasound, CT and MRI, 2020, 41(4): 357-365.
[44]Gelman J, Furr J. From open simple to roboticassisted
simple prostatectomy (RASP) for large benign prostate
hyperplasia: the time has come[J]. Journal of Endourology,
2020, 34(Suppl 1): S-2-S-6.
Refbacks
- 当前没有refback。
